{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:09:38Z","timestamp":1787785778830,"version":"build-2784847793"},"reference-count":41,"publisher":"Informa UK Limited","issue":"4-6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Patent Analyst"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/20468954.2025.2535943","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:31:08Z","timestamp":1754397068000},"page":"161-168","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Trispecific anti-CLDN-18.2\/CD3\/CD28 antibodies for gastric cancer treatment"],"prefix":"10.1080","volume":"13","author":[{"given":"Donaciano","family":"Flores-Robles","sequence":"first","affiliation":[{"name":"Universidad Aut\u00f3noma de Guerrero","place":["Guerrero, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Celestino","family":"Montes","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Guerrero","place":["Guerrero, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Antonio Perez","family":"Salda\u00f1a","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Guerrero","place":["Guerrero, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Del Razo-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Benem\u00e9rita Universidad Aut\u00f3noma de Puebla","place":["Puebla, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Sanchez-Esgua","sequence":"additional","affiliation":[{"name":"Benemerita Autonomous University of Puebla","place":["Puebla, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Perez-Santos","sequence":"additional","affiliation":[{"name":"Benemerita Autonomous University of Puebla","place":["Puebla, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0159"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/4946642"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12439"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2022.08.013"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S199827"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2219448"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000540071"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i26.5879"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-171163"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-1332-8"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.18502\/ijaai.v21i6.11519"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1824632"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02924-y"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245742"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020290"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02056-x"},{"key":"e_1_3_7_19_1","unstructured":"Sahin U Tureci O Usener D et al. Ganymed Pharmaceutical Johannes Gutenberg-Universitat Mainz Germany. Monoclonal antibodies against claudin-18 for treatment of cancer. United States patent US8168427. 2012 May 01."},{"key":"e_1_3_7_20_1","unstructured":"Sahin U Tureci O Brandeburg G et al. Ganymed Pharmaceutical Germany. A monoclonal antibodies against claudin-18 for treatment of cancer. United States patent US8425902. 2010 Jul 01."},{"key":"e_1_3_7_21_1","unstructured":"Sahin U Tureci O Usener D et al. Ganymed Pharmaceutical Johannes Gutenberg-Universitat Mainz Germany. Monoclonal antibodies against claudin-18 for treatment of cancer. United States patent US9212228. 2015 Dec 15."},{"key":"e_1_3_7_22_1","unstructured":"Sahin U Tureci O Usener D et al. Ganymed Pharmaceutical Johannes Gutenberg-Universitat Mainz Germany. Monoclonal antibodies against claudin-18 for treatment of cancer. United States patent US9499609. 2016 Nov 22."},{"key":"e_1_3_7_23_1","unstructured":"Sahin U Tureci O Usener D et al. Ganymed Pharmaceutical Johannes Gutenberg-Universitat Mainz Germany. Monoclonal antibodies against claudin-18 for treatment of cancer. United States patent US9751934. 2017 Sep 5."},{"key":"e_1_3_7_24_1","unstructured":"Sahin U Tureci O Usener D et al. Ganymed Pharmaceutical Johannes Gutenberg-Universitat Mainz Germany. Monoclonal antibodies against claudin-18 for treatment of cancer. United States patent US10174104. 2019 Jan 08."},{"key":"e_1_3_7_25_1","unstructured":"Sahin U Tureci O Usener D et al. Ganymed Pharmaceutical Johannes Gutenberg-Universitat Mainz Germany. Monoclonal antibodies against claudin-18 for treatment of cancer. United States patent US10017564. 2016 Jun 30."},{"key":"e_1_3_7_26_1","doi-asserted-by":"crossref","unstructured":"Sahin U Tureci O Usener D et al. Ganymed Pharmaceutical Johannes Gutenberg-Universitat Mainz Germany. Monoclonal antibodies against claudin-18 for treatment of cancer. United States patent US10738108. 2020 Aug 11.","DOI":"10.17147\/asu-2011-8859"},{"key":"e_1_3_7_27_1","unstructured":"Sahin U Tureci O Usener D et al. Ganymed Pharmaceutical Johannes Gutenberg-Universitat Mainz Germany. Monoclonal antibodies against claudin-18 for treatment of cancer. United States patent US11739139. 2023 Aug 29."},{"key":"e_1_3_7_28_1","unstructured":"Zhu G Ye J Qin J et al. Sparx therapeutics USA. Binding molecules specific for claudin 18.2 compositions and methods thereof for the treatment of cancer and other diseases. United States patent US11447551. 2022 Sep 20."},{"key":"e_1_3_7_29_1","unstructured":"Zhou Q Ch X Nian W et al. Shanghai Escugen biotechnology China. Claudin 18.2 antibody and use thereof. United States patent US2023096452. 2023 Mar 30."},{"key":"e_1_3_7_30_1","unstructured":"B-Ch A Kim SY Park MY et al. Y biologics. South Korea. Monoclonal antibody specifically binding to claudin-18.2 and use thereof. Worldwide patent WO2024136594. 2024 Jun 27."},{"key":"e_1_3_7_31_1","unstructured":"Sahin U Tureci O Korden W et al. Ganymed Pharmaceutical Johannes Gutenberg-Universitat Mainz Germany. Drug conjugates comprising antibodies against claudin 18.2. United States patent US11541127. 2023 Aug 31."},{"key":"e_1_3_7_32_1","unstructured":"Sahin U Stadler C Fischer L et al. Biontech Germany; Astellas Pharma Japan. Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and CD3 for treatment of claudin expressing cancer diseases. United States patent US11787862. 2019 Oct 10."},{"key":"e_1_3_7_33_1","unstructured":"Pei Y Lei M Huang H et al. Novarock Biotherapeutics USA. Bispecific binding proteins that bind CD137 and a tumor associated antigen. Worldwide patent WO2023034922. 2023 Mar 09."},{"key":"e_1_3_7_34_1","unstructured":"Sahin U Ch S Fischer L et al. BioNTech Germany; Astellas Pharma Japan. Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and CD3 for treatment of claudin expressing cancer diseases. United States patent US2024158501. 2024 May 16."},{"key":"e_1_3_7_35_1","unstructured":"Jiang J Luo X Gu J et al. Shanghai Qilu Pharmaceutical research and development Center China. Bispecific antibody for claudin18.2 and CD3 and application of bispecific antibody. United States patent US2024010748. 2024 Jan 11."},{"key":"e_1_3_7_36_1","unstructured":"Jiang W Fang L Wang Z et al. I-Mab Biopharma USA. Anti-claudin 18.2 and anti-4-IBB bispecific antibodies and uses thereof. United States patent US11261259. 2021 Oct 14."},{"key":"e_1_3_7_37_1","unstructured":"Zhu G Ye J Ma J et al. Sparx therapeutics USA bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1(PD-L1). United States US11970533. 2023 Jan 05."},{"key":"e_1_3_7_38_1","unstructured":"Afacan N Piscitelli C Newhook L et al. Zymeworks Canada. Trivalent and trispecific antibody constructs and methods of use thereof. Worldwide patent WO2024082060. 2024 Apr 25."},{"key":"e_1_3_7_39_1","volume-title":"Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts)","author":"Newhook L","year":"2023","unstructured":"Newhook L, Bhojane PP, Repenning PW, et al. TriTCE Co-stim, next generation costimulatory trispecific T cell engagers for the treatment of solid tumors. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts). Orlando, FL. Philadelphia (PA): AACR; 2023 Apr 14\u201319. Cancer Res. 83(7_Suppl):Abstract nr 5121 (2023)."},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-5121"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.81494"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2034355"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016243"}],"container-title":["Pharmaceutical Patent Analyst"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20468954.2025.2535943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:22:11Z","timestamp":1755613331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20468954.2025.2535943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":41,"journal-issue":{"issue":"4-6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/20468954.2025.2535943"],"URL":"https:\/\/doi.org\/10.1080\/20468954.2025.2535943","relation":{},"ISSN":["2046-8954","2046-8962"],"issn-type":[{"value":"2046-8954","type":"print"},{"value":"2046-8962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}